Weekly Report: what happened at PLX last week (1120-1124)?
Weekly Report · 1d ago
Weekly Report: what happened at PLX last week (1113-1117)?
Weekly Report · 11/20 11:28
Protalix BioTherapeutics: Fiscal Challenges And Gout Therapy Prospects
Prox-115, in phase i trials for refractory gout, is crucial in a competitive market with high efficacy and safety standards. Protalix shows mixed financials with declining revenue, yet improved operating loss. Significant share dilution and debt raise long-term sustainability concerns.
Seeking Alpha · 11/17 21:16
Protalix’s Regulatory Success and Promising Pipeline Drive Buy Rating: An Analysis of Potential Profitability and Growth
Analyst ram selvaraju from h.c. Wainwright has a buy rating and a 12-month price target of $10.00 for protalix (plx) the company's lead product candidate elfabrio received approval in the u.s. And eu in may.
TipRanks · 11/14 11:33
Weekly Report: what happened at PLX last week (1106-1110)?
Weekly Report · 11/13 11:21
American Well, Protalix BioTherapeutics among healthcare movers
Organigram ogi, msp recovery, protalix biotherapeutics among healthcare movers. s&p 500 health care sector adds 0.13% to 1486.15. american well, american well and acurx pharmaceuticals among healthcare sector losers.
Seeking Alpha · 11/06 15:01
Earnings Scheduled For November 6, 2023
Benzinga · 11/06 13:24
Protalix Biother: Current report
Press release · 11/06 13:02
Protalix Biother: Quarterly report
Press release · 11/06 13:01
Protalix BioTherapeutics Q3 23 Earnings Conference Call At 8:30 AM ET
NASDAQ · 11/06 12:30
Protalix BioTherapeutics Inc. Q3 loss drops in line with estimates
NASDAQ · 11/06 11:56
Protalix BioTherapeutics Q3 EPS $(0.04), Inline, Sales $10.35M Beat $10.00M Estimate
Protalix biotherapeutics reports quarterly losses of $0.04 per share. quarterly sales of $10.35 million beat the analyst consensus estimate by 3.45 percent. the company reported quarterly losses were 42.86 percent higher than the same period last year.
Benzinga · 11/06 11:51
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
PR Newswire · 11/06 11:50
Weekly Report: what happened at PLX last week (1030-1103)?
Weekly Report · 11/06 11:26
Notable earnings before Monday's open
Major earnings expected before the bell on monday include: axsome therapeutics, brookfield asset management and dish network. other major earnings slated for release before monday's open include: al, ceg, erj, bam, linc and bntx.
Seeking Alpha · 11/05 16:08
Earnings Preview For Protalix BioTherapeutics
Benzinga · 11/03 21:01
Protalix BioTherapeutics Q3 Earnings Preview
Seeking Alpha · 11/03 15:32
Amicus Therapeutics: The Right Play Now
Seeking Alpha · 10/31 16:24
Webull provides a variety of real-time PLX stock news. You can receive the latest news about Protalix Biother through multiple platforms. This information may help you make smarter investment decisions.
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Its ProCellEx platform is being used to manufacture approved and marketed product, Elelyso, for the treatment of Gaucher disease. The Company’s ProCellEx is its proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target pharmaceutical markets, including the product candidates, such as PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases, and others.